Promising Advances in Alzheimer’s Treatment: Anavex Life Sciences’ Blarcamesine Trial Shows Positive Results
In a groundbreaking study, Anavex Life Sciences recently unveiled encouraging results from their
phase 2b/3 trial of blarcamesine (ANAVEX2-73), a promising investigational
therapy for early-stage Alzheimer’s disease. The findings, published in
September 2023, highlight the potential of blarcamesine to significantly reduce
amyloid-ß biomarkers, a key pathological hallmark of Alzheimer’s, and slow
neurodegeneration.
Conducted across multiple centers and countries, the trial included 508 participants with early
symptomatic Alzheimer’s. Participants were divided into two groups, with 338
receiving blarcamesine and 170 receiving a placebo. Over the course of 48
weeks, the study utilized the Alzheimer’s Disease Assessment Scale-Cognitive
and Clinical Dementia Rating Scale to measure cognitive and functional
efficacy. The results showed statistically significant improvements in the
blarcamesine group compared to placebo, suggesting a slowing of cognitive
decline and brain atrophy.
Anavex’s trial’s findings are noteworthy as blarcamesine is one of the first therapies
to demonstrate a marked effect on Alzheimer’s disease biomarkers. Anavex Life
Sciences reported that the plasma Aβ42/40 ratio, a biomarker of amyloid-ß
pathology, significantly improved in patients treated with blarcamesine.
Moreover, MRI scans revealed a notable reduction in whole brain atrophy,
providing additional evidence of its impact on neurodegeneration.
Safety was closely monitored, with dizziness being the most common adverse event reported.
However, these episodes were mostly mild and transient, underscoring the
therapy’s favorable safety profile.
Christopher U Missling, PhD, CEO of Anavex, expressed optimism about the study’s results,
emphasizing the potential of blarcamesine as a convenient, orally administered
treatment option. The positive outcome from this trial marks a significant step
forward in Anavex Life Sciences’ quest to combat Alzheimer’s disease, offering
hope to millions affected worldwide.
Refer to this article for additional information.
Find more information about Anavex on https://www.cnn.com/markets/stocks/AVXL